TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04874233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug N = 20
Study: NCT04804267
Drug: LINZESS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
Study: NCT04804267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo orally once daily
Study: NCT06499168
Drug: neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy.
Study: NCT05576532
Drug: BCL2 Inhibitor plus IM2 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
Study: NCT06620796
Drug: second-line group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112+AK104+paclitaxel
Study: NCT05729386
Drug: GC2129A(Period 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Study: NCT05729386
Drug: GC2129A(Period 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Study: NCT05148234
Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
Study: NCT06390774
Drug: SSGJ-705
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 and anti-HER2 bispecific antibody
Study: NCT06444269
Drug: microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbubble Contrast non-FDA approved for route of administration
Study: NCT06668298
Drug: Sulfentanil
Normalized name: Sulfentanil citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
Study: NCT05521256
Drug: NNC0113-6856
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NN0113-6856 orally or intravenously.
Study: NCT05521256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
Study: NCT05408871
Drug: adnectin 18F-BMS-986192 Head and Neck Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
Study: NCT05781516
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
Study: NCT05254548
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
Study: NCT05026905
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
Study: NCT05720494
Drug: JZP441
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral study drug administered for up to 4 weeks
Study: NCT05720494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo administered for up to 4 weeks
Study: NCT04778059
Drug: USB002
Approvals — FDA: no, EMA: no, PMDA: no
Description: USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
Study: NCT04778059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
Study: NCT06622057
Drug: D07001-Softgel Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: D07001-softgel capsule is an oral gemcitabine.
Study: NCT06622057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
Study: NCT04802343
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, tablet.
Study: NCT04802343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, tablet.
Study: NCT05711862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Study: NCT04863365
Drug: PHP-201 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
Study: NCT06328400
Drug: Deuremidevir Hydrobromide for Suspension
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study: NCT06328400
Drug: Deuremidevir Hydrobromide for Suspension Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study: NCT05878119
Drug: Investigational Product - MIB 626
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
Study: NCT05878119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
Study: NCT05218356
Drug: Covidir injections
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
Study: NCT06621316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: at multiple dose levels (matching active arm HRS-7535 Tablet)
Study: NCT06623513
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
Study: NCT05911828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
Study: NCT05344742
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
Study: NCT06216535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo comparator
Study: NCT06061081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06457360
Drug: Ankaferd Blood Stopper
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of sterile gauze after extraction for hemostasis
Study: NCT05186246
Drug: Combination cream
Normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
Study: NCT05186246
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
Study: NCT05730244
Drug: Cassia alata extract
Normalized name: Dioscorea alata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml Cassia alata extract
Study: NCT05730244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml placebo solution
Study: NCT05461261
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg Prednisolone Acetate will be given orally twice a day during treatment.
Study: NCT05217238
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced intravenous injection of remifentanil before the rocuronium injection
Study: NCT05868356
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
Study: NCT05868356
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
Study: NCT06265272
Drug: Radiotracer Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan
Study: NCT05482321
Drug: Definity Suspension for Injection
Normalized name: Definity Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: * DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided).
Study: NCT05254639
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Study: NCT04946929
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: half amount low molecular weight heparin
Study: NCT06614998
Drug: Patients diagnosed with HLH-94 should be treated as soon as possible
Approvals — FDA: no, EMA: no, PMDA: no
Description: For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
Study: NCT05093530
Drug: Neumifil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Study: NCT05093530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Study: NCT05912049
Drug: 9MW3811 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenously infused on day 1
Study: NCT05912049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo intravenously infused on day 1
Study: NCT06666634
Drug: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
Study: NCT05573477
Drug: ATB-1011 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ATB-1011
Study: NCT05573477
Drug: ATB-1012 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ATB-1012
Study: NCT05573477
Drug: ATB-1013 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ATB-1013
Study: NCT04724629
Drug: Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator (Corticoids and antiretrovirals)
Study: NCT06667544
Drug: RNK08954-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment for a 3 week cycle
Study: NCT05287308
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
Study: NCT05287308
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
Study: NCT04498325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied by study
Study: NCT05571644
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Study: NCT06252051
Drug: Trivalent Influenza Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
Study: NCT05117554
Drug: casdatifan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05117554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05440240
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-Medrol
Study: NCT06537076
Drug: AR1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
Study: NCT06537076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for AR1005 to be administered BID for 20 weeks
Study: NCT04105946
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil administration intraoperatively in combination with other drugs used in TIVA
Study: NCT05499260
Drug: CB03-154
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB03-154 tablet once daily.
Study: NCT05499260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily.
Study: NCT06304805
Drug: cycle 1: treatment drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study: NCT06304805
Drug: cycle 1: reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study: NCT06304805
Drug: cycle 2: treatment drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study: NCT06304805
Drug: cycle 2: reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study: NCT06304805
Drug: cycle 3: treatment drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study: NCT06304805
Drug: cycle 3: reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study: NCT06200415
Drug: Glucosamine Sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
Study: NCT06621888
Drug: NTI164
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
Study: NCT00493662
Drug: Propylene Glycol 0.3%
Normalized name: PEG-400 0.4%/PROPYLENE GLYCOL 0.3% GEL,OPH
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06653608
Drug: Nano-reinforced calcium hydroxide medicament
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)
Study: NCT06653608
Drug: Calcium hydroxide without nanoparicles
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B ( Calcium hydroxide medicament without nanoparticles)
Study: NCT05791448
Drug: RNA Transcription Modulator AU-409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05863130
Drug: BI 764198 (C-14) (approach 1)
Normalized name: TRIOLEIN, 1-C-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198 (C-14) (approach 1)
Study: NCT06400459
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Study: NCT06400459
Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Study: NCT06400459
Drug: IVW-1001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVW-1001 Placebo
Study: NCT06416787
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI355 7.5mg/kg Q4W
Study: NCT06416787
Drug: IBI355
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI355 1mg/kg Q4W
Study: NCT06149065
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
Study: NCT05670561
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Study: NCT04641962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral